Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 8/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | STK10 | O94804 | 1/20 | 0.36 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSH | P09668 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CASP14 | P31944 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553372 | 0.91 | BCL6 (0.43) | BCL6RAB9ASOS1CTSVPLAT | |
| SCHEMBL5550350 | 0.89 | BCL6 (0.42) | BCL6RAB9ASOS1CTSVPLAT | |
| SCHEMBL5032200 | 0.88 | BCL6 (0.50) | BCL6RAB9ACTSVPLATCTSL | |
| SCHEMBL5031413 | 0.82 | RAB9A (0.54) | BCL6PTK6EGFRERBB2RAB9A | |
| SCHEMBL5549818 | 0.82 | CTSS (0.39) | BCL6RAB9ACTSVPLATCTSL | |
| SCHEMBL4840726 | 0.81 | RAB9A (0.41) | BCL6RAB9ASOS1CTSVPLAT | |
| SCHEMBL5553374 | 0.81 | RAB9A (0.37) | BCL6RAB9ACTSVPLATCTSL | |
| SCHEMBL5550320 | 0.81 | BCL6 (0.40) | BCL6EGFRRAB9ACTSLCTSS | |
| SCHEMBL5553411 | 0.80 | CTSS (0.38) | BCL6RAB9ACTSVPLATCTSL | |
| Hydrochloric Acid SCHEMBL5555475 | 0.80 | RAB9A (0.41) | BCL6RAB9ASOS1CTSVPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| WO-2005103015-A1 | TRIAZINE COMPOUNDS AND THEIR ANALOGS, COMPOSITIONS, AND METHODS | REDDY US THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-10-13 | — | — | US | claimed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2005103015-A1 | TRIAZINE COMPOUNDS AND THEIR ANALOGS, COMPOSITIONS, AND METHODS | REDDY US THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | MYLK, SMAD3, GID4 | BCL6 541/4885PTK6 1050/4885EGFR 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.